Zusammenfassung
Die akute Nierenschädigung („acute kidney injury“, AKI) hat bei kritisch kranken Patienten eine hohe Inzidenz und geht mit einer signifikant erhöhten Morbidität und Mortalität im Kurz- und Langzeitverlauf einher. Im Jahr 2012 wurden die KDIGO-Leitlinien (Kidney Disease Improving Global Outcome, KDIGO) publiziert, in denen evidenzbasierte praktische Empfehlungen zur Behandlung von Patienten mit AKI gegeben werden. Der 1. Teil der Leitlinien befasst sich mit der Vereinheitlichung von bisherigen Definitionen sowie der Schweregradeinteilung der AKI. In den weiteren Abschnitten wird unter Berücksichtigung der vorhandenen Evidenz auf Prävention, medikamentöse Therapie und Nierenersatztherapie bei Patienten mit AKI eingegangen. In jedem Abschnitt wird nach Darstellung der aktuellen Datenlage eine klare und gewichtete Behandlungsempfehlung ausgesprochen. Bei Nichtverfügbarkeit von spezifischen medikamentösen Therapien sind die wesentlichen Pfeiler einer effektiven Behandlung die frühe Diagnostik, die Vermeidung von Nephrotoxinen, eine aggressive hämodynamische Optimierung unter strikter Kontrolle des Volumenstatus sowie letztlich eine effektive, aber schonende Nierenersatztherapie.
Abstract
The incidence of acute kidney injury (AKI) in critically ill patients is very high and is associated with an increased morbidity and mortality. In 2012 the Kidney Disease: Improving Global Outcome (KDIGO) guidelines were published in which evidence-based practical recommendations are given for the evaluation and management of patients with AKI. The first section of the KDIGO guidelines deals with the unification of earlier consensus definitions and staging criteria for AKI. The subsequent sections of the guidelines cover the prevention and treatment of AKI as well as the management of renal replacement therapy (RRT) in patients with AKI. In each section the existing evidence is discussed and a specific treatment recommendation is given. The guidelines appreciates that there is insufficient evidence for many of the recommendations. As a specific pharmacological therapy is missing, an early diagnosis, aggressive hemodynamic optimization, tight volume control, and avoidance of nephrotoxic drugs are the only interventions to prevent AKI. If renal replacement therapy is required different modalities are available to provide an effective therapy with a low rate of adverse effects.
Literatur
Bellomo R, Kellum JA, Ronco C (2012) Acute kidney injury. Lancet 380:756–766
Rewa O, Bagshaw SM (2014) Acute kidney injury – epidemiology, outcomes and economics. Nat Rev Nephrol 10:193–207
Susantitaphong P et al (2013) World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 8:1482–1493
KDIGO AKI Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138
Atkins D et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490
Uhlig K et al (2006) Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70:2058–2065
Hoste EA et al (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10:R73
Uchino S et al (2006) An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 34:1913–1917
Bellomo R, Kellum JA, Ronco C (2004) Defining acute renal failure: physiological principles. Intensive Care Med 30:33–37
Kellum JA, Bellomo R, Ronco C (2007) The concept of acute kidney injury and the RIFLE criteria. Contrib Nephrol 156:10–16
Mehta RL et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31
Bagshaw SM et al (2008) A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 23:1203–1210
Thakar CV et al (2009) Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med 37:2552–2558
Joannidis M et al (2009) Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med 35:1692–1702
Amdur RL et al (2009) Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int 76:1089–1097
Coca SG et al (2009) Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53:961–973
Wald R et al (2009) Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302:1179–1185
Ad-hoc working group of ERBP et al (2012) A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 27:4263–4272
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266
Walsh M et al (2013) Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology 119:507–515
Asfar P et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583–1593
Bouchard J et al (2009) Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 76:422–427
Payen D et al (2008) A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 12:R74
Finfer S et al (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256
Annane D et al (2013) Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 310:1809–1817
Perner A et al (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134
Myburgh JA et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911
Yunos NM et al (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566–1572
Caironi P et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421
Russell JA et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887
De Backer D et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789
Rivers E et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377
Dellinger RP et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637
Lin SM et al (2006) A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 26:551–557
Donati A et al (2007) Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk surgical patients. Chest 132:1817–1824
Brienza N et al (2009) Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. Crit Care Med 37:2079–2090
Pro CI et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693
Berghe G van den et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367
Van den Berghe G et al (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354:449–461
Griesdale DE et al (2009) Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180:821–827
Investigators N.-S.S. et al (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283–1297
NICE-SUGAR Study Investigators et al (2012) Hypoglycemia and risk of death in critically ill patients. N Engl J Med 367:1108–1118
Karajala V, Mansour W, Kellum JA (2009) Diuretics in acute kidney injury. Minerva Anestesiol 75:251–257
Ho KM, Power BM (2010) Benefits and risks of furosemide in acute kidney injury. Anaesthesia 65:283–293
Cogliati AA et al (2007) Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth 21:847–850
Morelli A et al (2005) Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 33:2451–2456
Tumlin JA et al (2005) Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 46:26–34
Ding H et al (1993) Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 91:2281–2287
Friedlaender M et al (1995) Insulin-like growth factor-1 (IGF-1) enhances recovery from HgCl2-induced acute renal failure: the effects on renal IGF-1, IGF-1 receptor, and IGF-binding protein-1 mRNA. J Am Soc Nephrol 5:1782–1791
Franklin SC et al (1997) Insulin-like growth factor I preserves renal function postoperatively. Am J Physiol 272(2 Pt 2):F257–F259
Hirschberg R et al (1999) Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 55:2423–2432
Hladunewich MA et al (2003) A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF. Kidney Int 64:593–602
Bellomo R (2006) The epidemiology of acute renal failure: 1975 versus 2005. Curr Opin Crit Care 12:557–560
Bliziotis IA et al (2005) Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 80:1146–1156
Falagas ME, Matthaiou DK, Bliziotis IA (2006) The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57:639–647
Falagas ME et al (2007) Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 25:537–556
Paul M et al (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328:668
Paul M et al (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1:CD003344
Harbarth S et al (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:e120–e127
Ullmann AJ (2008) Nephrotoxicity in the setting of invasive fungal diseases. Mycoses 51(Suppl 1):25–30
Cornely OA et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37
ACT Investigators (2011) Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 124:1250–1259
Bouman CS et al (2002) Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 30:2205–2211
Karvellas CJ et al (2011) A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care 15:R72
Dubois MJ et al (2006) Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med 34:2536–2540
Prowle JR, Kirwan CJ, Bellomo R (2014) Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 10:37–47
Cruz DN et al (2010) Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 36:444–451
Liano F, Pascual J (1996) Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 50:811–818
Bagshaw SM et al (2006) Renal recovery after severe acute renal failure. Int J Artif Organs 29:1023–1030
Bellomo R et al (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361:1627–1638
Palevsky PM et al (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359:7–20
Uchino S et al (2009) Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study. Crit Care Med 37:2576–2582
O’Grady NP et al (2002) Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 23:759–769
Vascular Access Work Group (2006) Clinical practice guidelines for vascular access. Am J Kidney Dis 48(Suppl 1):S176–S247
Karakitsos D et al (2006) Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. Crit Care 10:R162
Leung J, Duffy M, Finckh A (2006) Real-time ultrasonographically-guided internal jugular vein catheterization in the emergency department increases success rates and reduces complications: a randomized, prospective study. Ann Emerg Med 48:540–547
Pronovost P (2008) Interventions to decrease catheter-related bloodstream infections in the ICU: the Keystone Intensive Care Unit Project. Am J Infect Control 36:S171 e1–e5
Jorres A et al (2013) A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. Nephrol Dial Transplant 28:2940–2945
Rabindranath K et al (2007) Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 3:CD003773
Pannu N et al (2008) Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 299:793–805
Bagshaw SM et al (2008) Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med 36:610–617
Schefold JC et al (2014) The effect of continuous versus intermittent renal replacement therapy on the outcome of critically ill patients with acute renal failure (CONVINT): a prospective randomized controlled trial. Crit Care 18:R11
Davenport A, Will EJ, Davison AM (1991) Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol 93:225–233
Davenport A, Will EJ, Davison AM (1990) Early changes in intracranial pressure during haemofiltration treatment in patients with grade 4 hepatic encephalopathy and acute oliguric renal failure. Nephrol Dial Transplant 5:192–198
Davenport A (2009) Continuous renal replacement therapies in patients with liver disease. Semin Dial 22:169–172
Davenport A (2009) Continuous renal replacement therapies in patients with acute neurological injury. Semin Dial 22:165–168
Levraut J et al (2003) Low exogenous lactate clearance as an early predictor of mortality in normolactatemic critically ill septic patients. Crit Care Med 31:705–710
Barenbrock M et al (2000) Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. Kidney Int 58:1751–1757
McLean AG et al (2000) Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction. Kidney Int 58:1765–1772
Tan HK, Uchino S, Bellomo R (2003) The acid-base effects of continuous hemofiltration with lactate or bicarbonate buffered replacement fluids. Int J Artif Organs 26:477–483
Zimmerman D et al (1999) Continuous veno-venous haemodialysis with a novel bicarbonate dialysis solution: prospective cross-over comparison with a lactate buffered solution. Nephrol Dial Transplant 14:2387–2391
Ronco C et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26–30
Schiffl H, Lang SM, Fischer R (2002) Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 346:305–310
Einhaltung ethischer Richtlinien
Interessenkonflikt. D. Kindgen-Milles erhielt Vortragshonorare und Forschungsunterstützung von Fresenius Medical Care sowie Vortragshonorare von Gambro und Bard. A. Jörres erhielt Vortragshonorare von Fresenius Medical Care und Gambro. S. John erhält Honorare als Mitglied eines „Medical Advisory Boards“ der Firma „Baxter-Gambro Renal“. A. Zarbock: keine Angabe. Der Beitrag enthält keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zarbock, A., John, S., Jörres, A. et al. Neue KDIGO-Leitlinien zur akuten Nierenschädigung. Anaesthesist 63, 578–588 (2014). https://doi.org/10.1007/s00101-014-2344-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00101-014-2344-5